Showing 2411-2420 of 5696 results for "".
- Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-in-china-screened-in-the-ongoing-ncx-470-denali-phase-3-trial-in-glaucoma/2480521/Nicox SA announced that the first patient has been screened in China in the ongoing Denali phase 3 clinical trial, opening the way for new drug application (NDA) submissions in both the United States and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma. Denali, wh
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin
- NIH Study Traces Molecular Link From Gene to Late-Onset Retinal Degenerationhttps://modernod.com/news/nih-study-traces-molecular-link-from-gene-to-late-onset-retinal-degeneration/2480510/Scientists have discovered that gene therapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease. Researchers from the National Eye Institute (NEI), part of the National Institutes of Health, generated a “dise
- Novartis Announces Positive Year 2 Results of Phase 3 KESTREL Study of Beovu in Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-positive-results-from-year-2-of-the-phase-3-trial-of-beovu-in-diabetic-macular-edema/2480504/Novartis announced the first interpretable results from year 2 (week 100) of the phase 3 KESTREL study. KESTREL assessed the safety and efficacy of Beovu (brolucizumab) 6 mg in patients with visual impairment due to diabetic macular edema (DME). Results from year 2 confirmed the visual acuit
- Recently Approved Presbyopia Eye Drop Vuity Now Available in Pharmacieshttps://modernod.com/news/recently-approved-presbyopia-eye-drop-vuity-now-available-in-pharmacies/2480503/Allergan announced that Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the FDA to treat presbyopia, is now available by prescription in pharmacies nationwide. "We are pleased to be able to bring this first-of-its
- Study: Warning Signs of Sight Loss Could be Identified Before Vision Deteriorateshttps://modernod.com/news/study-warning-signs-of-sight-loss-could-be-identified-before-vision-deteriorates/2480502/A new study has shown that the signs of age related macular degeneration can set in earlier than previously thought – even before patients begin to lose their sight. The findings open the door for research into earlier treatment that could help slow down the onset of the condition the most
- Treehouse Eyes Partners with J&J Vision to Deliver Treatment Innovation for Myopia Management: Acuvue Abiliti Overnight Therapeutic Lenseshttps://modernod.com/news/treehouse-eyes-partners-with-jj-vision-to-deliver-treatment-innovation-for-myopia-management-acuvue-abiliti-overnight-therapeutic-lenses/2480497/Treehouse Eyes, a health care business dedicated exclusively to treating myopic chi
- Ocular Therapeutix Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-topline-results-for-phase-2-clinical-trial-of-otx-ded-for-the-short-term-treatment-of-dry-eye-disease/2480496/Ocular Therapeutix announced positive topline results from its phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The phase 2 clinical trial is a US-based, randomized, double-masked, vehicle-controlled, m
- Amydis Has Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALShttps://modernod.com/news/amydis-has-pre-ind-meeting-with-the-fda-for-the-development-of-a-first-in-class-retinal-tracer-targeting-tdp43-for-the-diagnosis-of-als/2480493/Amydis announced the successful completion of a pre-IND (investigational new drug) meeting with the FDA regarding the development plans for a small-molecule tracer to detect TDP43 in the retina of amyotrophic lateral sclerosis (ALS) patients. The FDA agreed with the overall d
- CoFi Announces 300 Eye Care Practices Now Use CoFi’s Compliant Co-Management Payments Tool for Ophthalmology Procedureshttps://modernod.com/news/cofi-announces-300-eye-care-practices-now-use-cofis-compliant-co-management-payments-tool-for-ophthalmology-procedures/2480490/CoFi, a provider of a multi-party payments platform for elective medical procedures, announced the growing adoption of its co-management payment solution for ophthalmology procedures with more than 300 practices now using CoFi. Throughout ophthalmology, there i